Uterine leiomyomas, or fibroids, are the most common benign tumor in reproductive aged women. Affected women may remain asymptomatic or may report symptoms related to abnormal uterine bleeding, infertility, or pelvic pain and pressure. Depending on a patient's symptomatology and reproductive plans, treatment options include expectant management, medical management (hormonal and non-hormonal), or surgical management (myomectomy or hysterectomy). In those wishing to defer surgical management, non-hormonal therapies such as non-steroidal anti-inflammatory drugs and tranexamic acid have been shown to decrease menstrual blood loss. In patients with more symptomatic leiomyomas, hormonal therapies such as gonadotropin-releasing hormone agonists and selective progesterone receptor modulators are effective at reducing leiomyoma volume, uterine size, and menstrual blood loss. This manuscript will detail the available and emerging hormonal and non-hormonal treatments for symptomatic uterine leiomyomas.
|Titolo:||Role of Medical Management for Uterine Leiomyomas|
|Citazione:||Kashani, B.N., Centini, G., Morelli, S.S., Weiss, G., & Petraglia, F. (2016). Role of Medical Management for Uterine Leiomyomas. BAILLIERE'S BEST PRACTICE & RESEARCH. CLINICAL OBSTETRICS & GYNAECOLOGY, 34, 85-103.|
|Appare nelle tipologie:||1.1 Articolo in rivista|
File in questo prodotto:
|Role of Medical Management for Uterine Leiomyomas.pdf||PDF editoriale||NON PUBBLICO - Accesso privato/ristretto||Administrator Richiedi una copia|